AKBA - CIK 0001517022
Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2025 | $236.20M | +47.5% |
| FY 2024 | $160.18M | -17.7% |
| FY 2023 | $194.62M | -33.5% |
| FY 2022 | $292.48M | +38.2% |
| FY 2021 | $211.65M | -28.2% |
| FY 2020 | $294.64M | -12.0% |
| FY 2019 | $335.00M | +61.3% |
| FY 2018 | $207.74M | +14.6% |
| FY 2017 |
Akebia Therapeutics, Inc. (AKBA) reported revenue of $236.20M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2014 and fiscal 2025, Akebia Therapeutics, Inc.'s revenue grew from $0.00 to $236.20M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| $181.23M |
| +11706.3% |
| FY 2016 | $1.53M | - |
| FY 2015 | $0.00 | - |
| FY 2014 | $0.00 | - |